FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

The US FDA approved brexucabtagene autoleucel for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Efficacy was evaluated in ZUMA-3, a single-arm multicenter trial that evaluated brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor T-cell therapy, in adults with relapsed or refractory B-cell precursor ALL.
[US FDA]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Stress Hematopoiesis Induces a Proliferative Advantage in TET2 Deficiency

The authors developed a zebrafish tet2 mutant through which they showed that tet2 loss led to restricted hematopoietic differentiation combined with a modest upregulation of p53, which was also characteristic of many inherited bone marrow failure syndromes.
[Leukemia]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Comparison of the Blood, Bone Marrow, and Cerebrospinal Fluid Metabolomes in Children with B-Cell Acute Lymphoblastic Leukemia

Researchers profiled end-induction plasma, marrow, and cerebrospinal fluid (CSF) from ten children with b-cell acute lymphoblastic leukemia using liquid chromatography-mass spectrometry and observed plasma-marrow correlations for metabolites in pathways associated with end-induction residual disease and plasma-CSF correlations for a biomarker of fatigue.
[Scientific Reports]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Novel TCR-like CAR-T Cells to Target an HLA*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 Display Strong Activity against Acute Myeloid Leukemia

Researchers developed a T cell receptor-like antibody that binds Synovial Sarcoma X breakpoint 2 (SSX2) peptide 41-49 in the context of HLA-A*-0201.
[Molecular Therapy-Methods & Clinical Development]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

US FDA Approves Kite’s Tecartus® as the First and Only CAR T for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Kite, a Gilead Company announced the FDA has granted approval for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
[Kite]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Outcomes and Toxicity of Allogeneic Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second-Generation Tyrosine Kinase Inhibitors: A Prospective Non-Interventional Study from the Chronic Malignancy Working Party of the EBMT

Scientists presented the results of a prospective non-interventional study performed by the EBMT on 383 consecutive chronic myeloid leukemia patients previously treated with dasatinib or nilotinib undergoing allogeneic hematopoietic cell transplantation from 2009 to 2013.
[Bone Marrow Transplantation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies

The authors recruited 114 patients with B cell malignancies, comprising 77 acute lymphoblastic leukemia and 37 non-Hodgkin lymphoma patients, who were treated with CART19 cells.
[Journal of the National Cancer Institute]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Investigators conducted a multicenter, open-label, Phase II, single-arm study of pembrolizumab in patients with DIPSS intermediate 2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib.
[Blood Advances]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

Venetoclax plus Azacitidine and Donor Lymphocyte Infusion in Treating Acute Myeloid Leukemia Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Scientists evaluated the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion in treating patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
[Annals of Hematology]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Development and Characterization of a DNA Aptamer for MLL-AF9 Expressing Acute Myeloid Leukemia Cells Using Whole Cell-SELEX

Aptamers were selected against acute myeloid leukemia cells expressing the MLL-AF9 oncogene through systematic evolution of ligands by exponential enrichment (SELEX). Twelve rounds of SELEX, including two counter selections against fibroblast cells, were completed.
[Scientific Reports]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Spred1 Deficit Promotes Treatment Resistance and Transformation of Chronic Phase CML

Spred1 knockout, regardless if occurred in HSCs or in endothelial cells, increased miR-126 in LinSca-1+c-Kit+, a population enriched in leukemic stem cells (LSCs), resulting in expansion of LSCs, likely through hyperactivation of the MAPK/ERK pathway that augmented Bcl-2 expression and stability.
[Leukemia]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share
Share